Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHA-022121 oral prophylaxis for hereditary angioedema (Phase II, dose-ranging)
2021-000227-13Phase 2Active
- Sponsor
- Pharvaris
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucrictibant in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (4 arms), sponsored by Pharvaris. Started Nov 2021; status: active.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2021-000227-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000227-13.